Tech Company Financing Transactions
Feliqs Funding Round
On 7/1/2025, Feliqs raised $9 million in Series A financing from Beyond Next Ventures, FFG Venture Business Partners and Keio Innovation Initiative.
Transaction Overview
Company Name
Announced On
7/1/2025
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to accelerate the clinical development of FLQ-101, its lead candidate for the prevention of retinopathy of prematurity (ROP), to expand its operational and clinical development teams, accelerate key milestones in the U.S. clinical program, and strengthen collaborative research initiatives in the U.S.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1-1 Hyakunenkoen, Kurume
Fukuoka, 8390864,
Japan
Fukuoka, 8390864,
Japan
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
FELIQS is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university. To create the society without people left behind; In an aging society with a declining birthrate, it is important not only to extend healthy life expectancy, but also to maintain the number of healthy children. We try to solve the problems of both pediatric and aging diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ken-ichiro Kuninobu
Browse more venture capital transactions:
Prev: 7/1/2025: ProptechOS venture capital transaction
Next: 7/1/2025: Tailor K.K. venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs